Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 4.4% – Time to Sell?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) fell 4.4% on Monday . The stock traded as low as $26.25 and last traded at $26.29. 101,058 shares traded hands during mid-day trading, a decline of 48% from the average session volume of 195,626 shares. The stock had previously closed at $27.50.

Analyst Upgrades and Downgrades

DNTH has been the topic of a number of recent analyst reports. Cantor Fitzgerald assumed coverage on Dianthus Therapeutics in a research note on Thursday, June 27th. They issued an “overweight” rating on the stock. Wedbush decreased their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Robert W. Baird began coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They set an “outperform” rating and a $58.00 price target on the stock. Finally, Oppenheimer started coverage on Dianthus Therapeutics in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $48.00 price objective for the company. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $45.13.

Dianthus Therapeutics Stock Up 1.6 %

The business has a 50-day moving average price of $27.74 and a two-hundred day moving average price of $26.09. The company has a market capitalization of $820.89 million, a price-to-earnings ratio of -4.80 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The business had revenue of $1.86 million for the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. On average, sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new position in shares of Dianthus Therapeutics in the second quarter valued at approximately $112,000. The Manufacturers Life Insurance Company bought a new position in Dianthus Therapeutics during the 2nd quarter valued at $236,000. WINTON GROUP Ltd purchased a new position in Dianthus Therapeutics during the 2nd quarter worth $265,000. Point72 DIFC Ltd purchased a new position in Dianthus Therapeutics during the 2nd quarter worth $334,000. Finally, Virtu Financial LLC bought a new stake in shares of Dianthus Therapeutics in the 1st quarter worth $390,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.